PointState Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

PointState Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-95,935	Closed	-$14.7M	–	176
2021 Q1	$14.7M	Sell	95,935 -37,186	-28%	-$5.75M	0.29%	66
2020 Q4	$20.8M	Buy	133,121 +98,121	+280%	+$12.6M	0.39%	55
2020 Q3	$4M	Sell	35,000 -116,417	-77%	-$12.6M	0.11%	73
2020 Q2	$17M	Buy	151,417 +133,917	+765%	+$14.2M	0.51%	40
2020 Q1	$1.57M	Sell	17,500 -211,910	-92%	-$20.8M	0.08%	50
2019 Q4	$24.8M	Buy	+229,410	New	+$24.5M	0.45%	50
2019 Q2	–	Sell	-4,000	Closed	-$539K	–	165
2019 Q1	$539K	Buy	+4,000	New	+$497K	0.01%	121
2018 Q3	–	Sell	-707,800	Closed	-$87.9M	–	200
2018 Q2	$87.9M	Buy	707,800 +275,400	+64%	+$32.2M	0.99%	29
2018 Q1	$48.2M	Buy	+432,400	New	+$51.7M	0.52%	55
2017 Q2	–	Sell	-79,700	Closed	-$9.66M	–	183
2017 Q1	$9.66M	Sell	79,700 -1,029,250	-93%	-$133M	0.1%	100
2016 Q4	$136M	Buy	1,108,950 +915,250	+473%	+$112M	1.95%	13
2016 Q3	$23.7M	Buy	+193,700	New	+$24.9M	0.25%	70
2015 Q2	–	Sell	-110,000	Closed	-$19.1M	–	185
2015 Q1	$19.1M	Buy	+110,000	New	+$19.9M	0.26%	66

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

PointState Capital's ALXN Position: Q2 2021 in Review

PointState Capital sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 95,935 shares — an estimated $14.7M sold.

PointState Capital first reported a position in ALXN in Q1 2015 and held it in 13 quarters. The position peaked at $136M in Q4 2016. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

PointState Capital reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
PointState Capital sold 95,935 Alexion Pharmaceuticals shares in Q2 2021, an estimated $14.7M.
PointState Capital first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 13 quarters.
PointState Capital's Alexion Pharmaceuticals position peaked at $136M in Q4 2016.
710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on PointState Capital's 13F filing for Q2 2021, filed 13 Aug 2021.